---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032328"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:26:12.458750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M

## Summary
- Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.
- Net loss improved to $257K from $9.8M; adjusted EBITDA -$4.7M vs -$7.9M in prior year.
- Cash and equivalents $4.4M at June 30, 2024, up from $1.3M at Dec 31, 2023; raised $8.0M from May 2024 warrant exercises.
- Launched FDA-approved RhodoLED XL lamp in June; shipped first three machines within one week of launch.
- Took control of all US clinical trials for Ameluz on June 1, 2024, under amended license agreement to reduce costs.

## SEC filing metadata
- accession: 0001493152-24-032328
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/0001493152-24-032328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032328
- JSON: https://secwatch.observer/filing/0001493152-24-032328.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.